|1.||Fox, Alyson: 1 article (09/2010)|
|2.||Sharkey, Keith A: 1 article (09/2010)|
|3.||Lutz, Beat: 1 article (09/2010)|
|4.||Duncan, Marnie: 1 article (09/2010)|
|5.||Keenan, Catherine M: 1 article (09/2010)|
|6.||Cluny, Nina L: 1 article (09/2010)|
|7.||Brusberg, Mikael: 1 article (02/2009)|
|8.||Kang, Daiwu: 1 article (02/2009)|
|9.||Martinez, Vicente: 1 article (02/2009)|
|10.||Lindström, Erik: 1 article (02/2009)|
09/01/2010 - "SAB378 did not reduce the degree of colitis induced by DSS or TNBS. "
09/01/2010 - "SAB378 was not effective against two models of experimental colitis, which may indicate that peripheral cannabinoid receptor stimulation alone may not be sufficient to mediate the anti-inflammatory effects of cannabinoids."
09/01/2010 - "The potential for SAB378 to modify inflammation was studied by using dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) models of experimental colitis. "
09/01/2010 - "Using the peripherally restricted cannabinoid (CB)(1)/CB(2) receptor agonist naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), we investigated the role of peripheral cannabinoid receptors in the regulation of GI motility and the development of colitis in mice. "
09/01/2010 - "Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice."
|1.||naphthalen- 1- yl- (4- pentyloxynaphthalen- 1- yl)methanone
|2.||CB2 Cannabinoid Receptor
|3.||Cannabinoid Receptors (Cannabinoid Receptor)